Chromogranin A, a member of Neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma
Abstrakt
The function of chromogranin A (CGA) is reviewed, and the radioimmunometric determination of plasma CGA was evaluated as a marker of pheochromocytoma using a comparison of pheochromocytoma patients immediately before surgery (group P, n=25, 635 +/- 451 ng/ml) with other groups of patients, i.e. pheochromocytoma patients approximately I year after removal of tumor (group PP, n=13, 69 +/- 33 ng/ml), medullary thyroid carcinoma patients (group M, n=22, 106 +/- 59 ng/ml), congenital adrenal hyperplasy patients (n=33, 65 +/- 40 ng/ml), and controls (n=31, 66 +/- 29 ng/ml). A CGA level above cut off value 130 ng/ml was found in 24 of 25 patients in group P, 1 (relapse) of 13 patients in group PP, and 4 of 22 patients in group M.
In the group P we found a significant association between the size of the tumors removed and plasma CGA concentrations (p=0.0016), and also a significant (p=0.0016) relationship between plasma CGA concentrations and PASS score rating the malignity of pheochromocytoma. We can conclude that plasma CGA concentration as determined by radioimmunometric assay (which is simple without the necessity of special laboratory equipment) is an effective marker of pheochromocytoma with association to malignity and tumor mass.